Seek and Destroy: Relating Cancer Drivers to Therapies

Emmanuel Martinez-Ledesma; John F. deGroot; Roel G.W. Verhaak

doi:10.1016/j.ccell.2015.02.011

Seek and Destroy: Relating Cancer Drivers to Therapies

Emmanuel Martinez-Ledesma, John F. deGroot, Roel G.W. Verhaak

Research output: Contribution to journal › Short survey › peer-review

4 Scopus citations

Abstract

In this issue of Cancer Cell, Rubio-Perez and colleagues present an insilico prescription strategy based on identifying somatic driver alterations and druggability options. Although relatively few patients were found treatable following current clinical guidelines, many more could benefit from drug repurposing, considering compounds at various stages of (pre-)clinical investigation. In this issue of Cancer Cell, Rubio-Perez and colleagues present an insilico prescription strategy based on identifying somatic driver alterations and druggability options. Although relatively few patients were found treatable following current clinical guidelines, many more could benefit from drug repurposing, considering compounds at various stages of (pre-)clinical investigation.

Original language	English (US)
Pages (from-to)	319-321
Number of pages	3
Journal	Cancer cell
Volume	27
Issue number	3
DOIs	https://doi.org/10.1016/j.ccell.2015.02.011
State	Published - Mar 9 2015

ASJC Scopus subject areas

Oncology
Cell Biology
Cancer Research

MD Anderson CCSG core facilities

Bioinformatics Shared Resource

Access to Document

10.1016/j.ccell.2015.02.011

Cite this

@article{06bcd150c67846eaa6a648422b88a7e4,

title = "Seek and Destroy: Relating Cancer Drivers to Therapies",

abstract = "In this issue of Cancer Cell, Rubio-Perez and colleagues present an insilico prescription strategy based on identifying somatic driver alterations and druggability options. Although relatively few patients were found treatable following current clinical guidelines, many more could benefit from drug repurposing, considering compounds at various stages of (pre-)clinical investigation. In this issue of Cancer Cell, Rubio-Perez and colleagues present an insilico prescription strategy based on identifying somatic driver alterations and druggability options. Although relatively few patients were found treatable following current clinical guidelines, many more could benefit from drug repurposing, considering compounds at various stages of (pre-)clinical investigation.",

author = "Emmanuel Martinez-Ledesma and deGroot, {John F.} and Verhaak, {Roel G.W.}",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

month = mar,

day = "9",

doi = "10.1016/j.ccell.2015.02.011",

language = "English (US)",

volume = "27",

pages = "319--321",

journal = "Cancer cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "3",

}

TY - JOUR

T1 - Seek and Destroy

T2 - Relating Cancer Drivers to Therapies

AU - Martinez-Ledesma, Emmanuel

AU - deGroot, John F.

AU - Verhaak, Roel G.W.

PY - 2015/3/9

Y1 - 2015/3/9

N2 - In this issue of Cancer Cell, Rubio-Perez and colleagues present an insilico prescription strategy based on identifying somatic driver alterations and druggability options. Although relatively few patients were found treatable following current clinical guidelines, many more could benefit from drug repurposing, considering compounds at various stages of (pre-)clinical investigation. In this issue of Cancer Cell, Rubio-Perez and colleagues present an insilico prescription strategy based on identifying somatic driver alterations and druggability options. Although relatively few patients were found treatable following current clinical guidelines, many more could benefit from drug repurposing, considering compounds at various stages of (pre-)clinical investigation.

AB - In this issue of Cancer Cell, Rubio-Perez and colleagues present an insilico prescription strategy based on identifying somatic driver alterations and druggability options. Although relatively few patients were found treatable following current clinical guidelines, many more could benefit from drug repurposing, considering compounds at various stages of (pre-)clinical investigation. In this issue of Cancer Cell, Rubio-Perez and colleagues present an insilico prescription strategy based on identifying somatic driver alterations and druggability options. Although relatively few patients were found treatable following current clinical guidelines, many more could benefit from drug repurposing, considering compounds at various stages of (pre-)clinical investigation.

UR - http://www.scopus.com/inward/record.url?scp=84924246691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924246691&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2015.02.011

DO - 10.1016/j.ccell.2015.02.011

M3 - Short survey

C2 - 25759016

AN - SCOPUS:84924246691

SN - 1535-6108

VL - 27

SP - 319

EP - 321

JO - Cancer cell

JF - Cancer cell

IS - 3

ER -

Seek and Destroy: Relating Cancer Drivers to Therapies

Abstract

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this